life science investing C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
life science investing C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC
Sun Summit Commences Drilling and Provides Exploration Update from the JD Project in BC's Toodoggone District
